EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudieOpen Access · CC BY-NC 4.0

The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease

Akhilesh Swaminathan iD, James M Fulforth, Chris M Frampton, Grace M Borichevsky, Thomas C Mules iD, Kate Kilpatrick, Myriam Choukour, Peter Fields, Resham Ramkissoon, Emily Helms, Stephen B Hanauer, Rupert W Leong und 3 weitere

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad294 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Akhilesh Swaminathan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Otago, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Severity of Illness Index, Quality of Life, Disease Progression. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The disease severity index (DSI) for inflammatory bowel disease (IBD) combines measures of disease phenotype, inflammatory activity, and patient-reported outcomes. We aimed to validate the DSI and assess its utility in predicting a complicated IBD course.

Methods

A multicenter cohort of adults with IBD was recruited. Intraclass correlation coefficients (ICCs) and weighted Kappa assessed inter-rater reliability. Cronbach’s alpha measured internal consistency of DSI items. Spearman’s rank correlations compared the DSI with endoscopic indices, symptom indices, quality of life, and disability. A subgroup was followed for 24 months to assess for a complicated IBD course. Area under the receiver operating characteristics curve (AUROC) and multivariable logistic regression assessed the utility of the DSI in predicting disease progression.

Results

Three hundred and sixty-nine participants were included (Crohn’s disease [CD], n = 230; female, n = 194; mean age, 46 years [SD, 15]; median disease duration, 11 years [interquartile range, 5-21]), of which 171 (CD, n = 99; ulcerative colitis [UC], n = 72) were followed prospectively. The DSI showed inter-rater reliability for CD (ICC 0.93, n = 65) and UC (ICC 0.97, n = 33). The DSI items demonstrated inter-rater agreement (Kappa > 0.4) and internal consistency (CD, α > 0.59; UC, α > 0.75). The DSI was significantly associated with endoscopic activity (CDn=141, r = 0.65, P < .001; UCn=105, r = 0.80, P < .001), symptoms (CDn=159, r = 0.69, P < .001; UCn=132, r = 0.58, P < .001), quality of life (CDn=198, r = −0.59, P < .001; UCn=128, r = −0.68, P < .001), and disability (CDn=83, r = −0.67, P < .001; UCn=52, r = −0.74, P < .001). A DSI of 23 best predicted a complicated IBD course (AUROC = 0.82, P < .001) and was associated with this end point on multivariable analyses (aOR, 9.20; 95% confidence interval, 3.32-25.49).

Conclusions

The DSI reliably encapsulates factors contributing to disease severity and accurately prognosticates the longitudinal IBD course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Severity of Illness IndexQuality of LifeDisease ProgressionHumansFemaleMaleMiddle AgedAdultReproducibility of ResultsColitis, UlcerativeProspective StudiesCrohn DiseaseInflammatory Bowel DiseasesROC CurvePatient Reported Outcome Measures

Stichwörter der Autor:innen

inflammatory bowel diseaseoutcomes researchsymptom score or index

Autor:innen und Institutionen

  • Department of Medicine, University of Otago, Christchurch, New Zealand.
  • Department of Gastroenterology, Christchurch Hospital, New Zealand.
  • Department of Gastroenterology, Waikato Hospital, Hamilton, New Zealand.
  • Centre Hospitalier Régional Universitaire (CHRU) Nancy, Délégation à la Recherche Clinique et à l'Innovation, Plateforme Maladies Inflammatoires Chroniques de l'Intestin (MICI), Vandoeuvre-lès-Nancy, France.
  • Division of Gastroenterology and Hepatology, School of Medicine & Dentistry, University of Rochester, Rochester, NY, USA.
  • Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Akhilesh Swaminathan, Thomas C Mules, Corey A Siegel

Zitieren

APA

Swaminathan, A., Fulforth, J. M., Frampton, C. M., Borichevsky, G. M., Mules, T. C., Kilpatrick, K., Choukour, M., Fields, P., Ramkissoon, R., Helms, E., Hanauer, S. B., Leong, R. W., Peyrin-Biroulet, L., Siegel, C. A., & Gearry, R. B. (2024). The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad294

Vancouver

Swaminathan A, Fulforth JM, Frampton CM, Borichevsky GM, Mules TC, Kilpatrick K, et al. The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad294

BibTeX
@article{Swaminathan2024,
  author = {Swaminathan, Akhilesh and Fulforth, James M and Frampton, Chris M and Borichevsky, Grace M and Mules, Thomas C and Kilpatrick, Kate and Choukour, Myriam and Fields, Peter and Ramkissoon, Resham and Helms, Emily and Hanauer, Stephen B and Leong, Rupert W and Peyrin-Biroulet, Laurent and Siegel, Corey A and Gearry, Richard B},
  title = {The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad294}
}
Kostenlos starten →